This trial is active, not recruiting.

Condition neovascular age-related macular degeneration
Treatments bevacizumab, bevacizumab + triamcinolone acetonide
Phase phase 3
Target VEGF
Sponsor Shahid Beheshti Medical University
Start date November 2005
Trial identifier NCT00370370, 8533


To compare the efficacy and safety results of intravitreal bevacizumab alone with bevacizumab + triamcinolone acetonide in neovascular AMD.

United States No locations recruiting
Other countries No locations recruiting

Study Design

Allocation randomized
Endpoint classification safety/efficacy study
Intervention model parallel assignment
Masking single blind (subject)
Primary purpose treatment
(Active Comparator)
Injection of intravitreal bevacizumab
Injection of intravitreal bevacizumab
(Active Comparator)
Injection of bevacizumab + triamcinolone acetonide
bevacizumab + triamcinolone acetonide
Injection of bevacizumab + triamcinolone acetonide

Primary Outcomes

visual acuity
time frame:

Secondary Outcomes

central macular thickness
time frame:
leakage in fluorescein angiography
time frame:
intraocular pressure
time frame:
anterior chamber reaction
time frame:

Eligibility Criteria

Male or female participants at least 50 years old.

Inclusion Criteria: - Cases of active neovascular AMD with visual acuity of 20/400- 20/40 Exclusion Criteria: - History of glaucoma or ocular hypertension - Disciform scar

Additional Information

Principal investigator Hamid Ahmadieh, MD
Trial information was received from ClinicalTrials.gov and was last updated in June 2008.
Information provided to ClinicalTrials.gov by Shahid Beheshti Medical University.